NTRA
$198.38
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of tre...
Recent News
A Look At Natera (NTRA) Valuation After New Signatera Data And Zenith Genomics Launch
Natera (NTRA) is back in focus after publishing new peer reviewed data on its Signatera cancer assay and rolling out the Zenith genomics rare disease platform. These developments sharpen attention on the stock’s recent performance. See our latest analysis for Natera. The latest Signatera data and Zenith launch have come alongside a 1-day share price return of 5.23% to US$197.68. This comes even as the 30-day share price return is 4.15% lower and the 1-year total shareholder return stands at...
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries.
3 Growth Stocks to Add to Your Roster
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment
Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.
NTRA Debuts Zenith Genomics Next-Gen Sequencing Test for Rare Diseases
Natera launches Zenith genomics whole-genome sequencing assay with MyOme to boost rare disease detection and expand diagnostics reach across the United States.